Abstract
The clinical manifestation of Premature Ovarian Insufficiency (POI) is largely attributed due to the follicular atresia caused by excessive senescence, apoptosis, and loss of ovarian granulosa cells (OGC) resulting in the decreased number of follicles. microRNA144-5p has been reported to be downregulated in the plasma of POI patients and overexpression of miRNA can attenuate the damage in preclinical studies. This study aims to use a lentiviral-based transfection method to overexpress miR144-5p in human Bone Marrow Mesenchymal Stem Cells (hBM-MSCs) and evaluate the therapeutic effect of its secretome using an in vitro POI model.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
